Sunifiram
Sunifiram (DM-235) is a 2000s Italian-academic compound from the Università di Firenze that showed extreme potency in rodent memory models — meaningful effect at 0.001-0.1 mg/kg, which is roughly 1… | Compound
Aliases (2)
▸ Overview TL;DR
Sunifiram (DM-235) is a 2000s Italian-academic compound from the Università di Firenze that showed extreme potency in rodent memory models — meaningful effect at 0.001-0.1 mg/kg, which is roughly 1000× more potent than piracetam. None of that has ever been tested in humans. Sold as research chemistry only. The serious modern equivalent is TAK-653.
▸ Mechanism of action
Sunifiram is structurally a piperazine derivative — not a racetam ring, but functionally classified as racetam-adjacent because of similar behavioral effects in animals. Mechanism work suggests:
- Indirect AMPA potentiation: Increases AMPA-mediated currents and enhances long-term potentiation (LTP) in hippocampal slices. Effect is blocked by AMPA antagonists.
- NMDA glycine-site partial agonism: Binds at the glycine modulatory site of the NMDA receptor (the same site DCS, sarcosine, and glycine itself act on). This is the proposed bridge to its memory-enhancing effects.
- Cholinergic enhancement: In rodents, sunifiram increases hippocampal acetylcholine release in microdialysis studies, comparable to nicotinic agonists.
- Net effect: Glutamatergic + cholinergic potentiation — a combination that hits the two main substrates of declarative memory.
Compared to IDRA-21 (a Type-II ampakine that aggressively blocks AMPA desensitization), sunifiram is gentler and more indirect — the seizure liability profile is consequently lower, but still nonzero.
▸ Pharmacokinetics No data
▸ What to expect Generic
- 1Week 1Tolerability and dose-response.
- 2Week 2-4Early effect window.
- 3Week 4-8Peak benefit assessment.
- 4Week 8+Cycle decision point.
▸ Side effects + safety
- Common (forum): Headache, mild jitter, irritability, insomnia if late-dosed
- Less common: GI upset, anxiety, brain fog (paradoxical) at higher doses or daily use
- Rare-serious: Seizure-threshold concerns are mechanism-driven and forum-anecdote-supported; no published case reports because no clinical population exists.
- Specific watch periods: N/A — no human safety dataset.
▸Interactions5 compounds
- Cholinergic precursors (alpha-GPC, citicoline):SynergisticForum-popular pairing — AMPA potentiation increases ACh demand, so a cholinergic floor reduces headache risk.
- Aniracetam:SynergisticTheoretically additive AMPA potentiation; risk = compounded seizure threshold reduction.
- Other ampakines, IDRA-21, TAK-653:AvoidAdditive AMPA modulation = additive seizure risk.
- Bupropion, tramadol, high-dose modafinil:AvoidIndependent seizure liability.
- Sleep deprivation:AvoidLowers seizure threshold.